This Simple Treatment Could Help Thousands Beat Hepatitis C infection

Recent findings have shed light on how well two commonly used treatments work for hepatitis C virus infection among individuals who use drugs, often by injection. The research compared the antiviral regimens sofosbuvir/velpatasvir, a combination therapy that targets the hepatitis C virus to stop it from replicating, and glecaprevir/pibrentasvir, another antiviral combination that also prevents the virus from multiplying in the body, in a population facing multiple health and social challenges, offering real-world data on their safety and efficacy.

Researchers led by Dr. Brian Conway from the Vancouver Infectious Diseases Centre, in partnership with Simon Fraser University, conducted the study, which was published in the Journal of Virus Eradication. Their research aimed to determine whether one treatment was superior to the other in achieving hepatitis C virus cure rates, as measured by the absence of detectable virus 12 or more weeks after the completion of therapy.

The study evaluated an equal number of individuals in both treatment groups, all of whom were actively using or injecting drugs. The results demonstrated that both regimens achieved exceptionally high cure rates, with nearly all participants completing treatment successfully. Notably, both regimens proved to be highly effective even among those with significant barriers to healthcare, such as unstable housing and simultaneous use of fentanyl, a strong opioid associated with significant drug overdose events as well as disengagement from care.

A key finding was that most participants completed their treatment, highlighting the importance of community-based healthcare support. “We found that engagement in a structured program significantly improved adherence and outcomes, reinforcing the need for accessible treatment strategies,” said Dr. Conway. Despite these interventions, a few overdose-related deaths still occurred among participants during the study period, emphasizing the ongoing challenges of addiction and the necessity for integrated support programs aimed at reducing these health risks. Participation in programs such as those implemented by Dr. Conway’s group led to an increased use of harm reduction interventions, such as needle exchanges and supervised drug use facilities, serving to minimize health risks for drug users.

It is important to note that participants using glecaprevir and pibrentasvir and sofosbuvir and velpatasvir exhibited comparable initial health and lifestyle factors used for comparison in research, including rates of Indigenous representation, housing instability, and fentanyl use. The findings suggest that both treatments can thus be confidently offered to the entire target population without concerns over significant differences in success rates or safety profiles.

With worldwide efforts to eliminate HCV infection as a public health concern by 2030, this study underscores the importance of easy-to-access treatment options and locally driven healthcare solutions. “Our data supports offering both treatment options in this vulnerable population, reassuring us that whatever option is selected (one pill a day for 12 weeks with sofosbuvir/velpatasvir or 3 pills a day for 8 weeks with glecaprevir/pibrentasvir), a highly effective therapeutic regimen will be provided,” Dr. Conway concluded.